Prior approval opinions of independent directors on employing the company’s audit institution in 2022
In accordance with the Listing Rules of Shenzhen Stock Exchange, the governance standards of listed companies, the guidance on the establishment of independent director system in listed companies, the articles of association, the independent director system and other relevant laws and regulations, as independent directors of Berry Genomics Co.Ltd(000710) (hereinafter referred to as “the company”), we have carefully reviewed the company’s proposal on employing the company’s audit institution in 2022. Based on the position of independent judgment, we express our prior approval opinions on the company’s engagement of an audit institution in 2022: 1. Shanghui Certified Public Accountants (special general partnership) has the qualification of securities and futures related business. During the period of serving as the company’s audit institution, it can follow the independent, objective and impartial professional standards, and the audit report issued for the company can objectively and truly reflect the actual situation of the company The financial situation and operating results have better fulfilled the responsibilities and obligations of both parties.
2. In order to ensure the consistency of the audit work, we agree to continue to employ Shanghui accounting firm (special general partnership) as the company’s audit institution in 2022 to be responsible for the company’s financial audit and internal control audit in 2022, and agree to submit the above proposal to the 16th meeting of the ninth board of directors for deliberation. Independent directors: Wang Xiuping, Li Guangchao, Wang Sijia April 14, 2022
